Petvivo Hldgs Inc Stock Price, News & Analysis

PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) announced a successful showcase of its product, Spryng^™, at the American Association of Equine Practitioners (AAEP) conference from December 4-8, 2021. Spryng utilizes OsteoCushion^™ Technology for treating lameness and joint issues like osteoarthritis. The company received positive feedback from veterinarians, indicating strong interest in adopting Spryng. PetVivo is offering a promotional deal through December 31, 2021, providing an extra syringe for every five purchased. The company plans expanded sales of Spryng in Q4 2021.

PetVivo Holdings, Inc. (NASDAQ: PETV) will participate in the American Association Equine Practitioners (AAEP) conference from December 4-8, 2021, in Nashville, TN. The company aims to showcase its lead product, SPRYNG^™, featuring OsteoCushion^™ Technology, designed to treat lameness and joint issues, including osteoarthritis, in pets. The AAEP conference is expected to draw over 5,000 industry professionals, presenting opportunities for networking and business development. The company plans to expand commercial sales of SPRYNG in Q4 2021.

PetVivo Holdings announces a comprehensive digital media campaign to promote its product Spryng™, targeting improvements in animal lameness. The campaign includes 40 interviews and 600 T.V. commercials over the next year on major networks like Newsmax and Bloomberg. Additionally, 2,400 digital billboard ads will be displayed daily in Manhattan. Spryng™, which aids osteoarthritis in pets, is set for expanded sales this quarter. PetVivo aims to leverage veterinary opportunities similar to human therapies, supported by a robust patent portfolio.

PetVivo Holdings raised approximately $11.25 million through an Initial Public Offering, rebranding Kush™ as Spryng™ and initiating sales. In Q2 2022, revenue reached $4,977, up from $4,790 in Q2 2021. The company reported a net loss of $1,105,474, improved from $1,348,002 in the same period last year. For the six months ended September 30, 2021, revenue was $9,122. The company aims to utilize offering proceeds to enhance sales and marketing efforts and has made key management hires.

PetVivo Holdings, Inc. (Nasdaq: PETV, PETVW) raised approximately $11.25 million through an Initial Public Offering, rebranding Kush™ to Spryng™. As of September 30, 2021, revenues increased to $4,977 for Q2 2021 from $4,790 in Q2 2020. Net loss decreased to ($1,105,474) compared to ($1,348,002) year-over-year. Significant investments in sales, marketing, and research were made to support the launch of Spryng™. Key management hires were also announced.

PetVivo Holdings, Inc. will release its financial results for Q2 FY 2022 on November 15, 2021, post-market. A conference call is scheduled for 4:00 p.m. CT to discuss these results. The call will be available via webcast on their Investor Relations website. PetVivo focuses on innovative medical devices for animals, leveraging human therapies to expedite market entry. They have a pipeline of 17 products and 21 patents, with their lead product, SPRYNG™, aimed at treating osteoarthritis in dogs and horses, set for expanded sales this quarter.

PetVivo Holdings, Inc. (NASDAQ: PETV) has appointed Kick as its advertising agency to enhance its branding and marketing strategies. Kick, known for its extensive experience in the animal industry, will assist PetVivo in advertising, digital media, and experiential marketing. CEO John Lai emphasized Kick's strong commitment to impactful messaging and innovative solutions. PetVivo is focused on developing therapeutic devices for animals, notably its flagship product, Spryng with OsteoCushion Technology, aimed at treating osteoarthritis in companion animals, set for expanded commercialization in Q4 2021.

PetVivo Holdings, Inc. (NASDAQ: PETV) has appointed Joe Manning, DVM, as Senior Technical Veterinarian. Dr. Manning, with over 30 years in the veterinary field, is expected to enhance product development and commercialization of PetVivo's therapeutics for animals. His expertise includes a strong background in marketing and sales for veterinary products. The company aims to leverage human therapies for animal treatment, aiming for accelerated market entry compared to traditional pharmaceuticals. Their lead product, SPRYNG™, will see expanded commercial sales in Q4 2021.